KR102487451B1 - Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물 - Google Patents

Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물 Download PDF

Info

Publication number
KR102487451B1
KR102487451B1 KR1020217002019A KR20217002019A KR102487451B1 KR 102487451 B1 KR102487451 B1 KR 102487451B1 KR 1020217002019 A KR1020217002019 A KR 1020217002019A KR 20217002019 A KR20217002019 A KR 20217002019A KR 102487451 B1 KR102487451 B1 KR 102487451B1
Authority
KR
South Korea
Prior art keywords
methyl
acrylamide
pyrazol
ylamino
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217002019A
Other languages
English (en)
Korean (ko)
Other versions
KR20210011068A (ko
Inventor
서병철
파레쉬 데비다스 살가온카
이재규
고종성
송호준
이인용
이재상
정동식
김정호
김세원
Original Assignee
주식회사유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102487451(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 주식회사유한양행 filed Critical 주식회사유한양행
Priority to KR1020237000623A priority Critical patent/KR102662358B1/ko
Publication of KR20210011068A publication Critical patent/KR20210011068A/ko
Application granted granted Critical
Publication of KR102487451B1 publication Critical patent/KR102487451B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)
KR1020217002019A 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물 Active KR102487451B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237000623A KR102662358B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13
US62/063,394 2014-10-13
PCT/KR2015/010784 WO2016060443A2 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
KR1020207002949A KR102208775B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207002949A Division KR102208775B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237000623A Division KR102662358B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물

Publications (2)

Publication Number Publication Date
KR20210011068A KR20210011068A (ko) 2021-01-29
KR102487451B1 true KR102487451B1 (ko) 2023-01-11

Family

ID=55654993

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020217002019A Active KR102487451B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
KR1020237000623A Active KR102662358B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
KR1020207002949A Active KR102208775B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
KR1020177012969A Active KR102073854B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
KR1020247013986A Pending KR20240074820A (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020237000623A Active KR102662358B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
KR1020207002949A Active KR102208775B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
KR1020177012969A Active KR102073854B1 (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
KR1020247013986A Pending KR20240074820A (ko) 2014-10-13 2015-10-13 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물

Country Status (30)

Country Link
US (2) US9593098B2 (enExample)
EP (4) EP3929190B1 (enExample)
JP (3) JP6524221B2 (enExample)
KR (5) KR102487451B1 (enExample)
CN (2) CN111686110B (enExample)
AU (1) AU2015331166B2 (enExample)
BR (1) BR112017007769B1 (enExample)
CA (1) CA2962914C (enExample)
CY (2) CY1122737T1 (enExample)
DK (3) DK3207035T3 (enExample)
ES (3) ES2770058T3 (enExample)
FI (2) FI3929190T3 (enExample)
FR (1) FR25C1021I1 (enExample)
HR (3) HRP20250213T1 (enExample)
HU (4) HUE048006T2 (enExample)
LT (4) LT3604294T (enExample)
MX (3) MX385942B (enExample)
NL (1) NL301329I2 (enExample)
NO (1) NO2025025I1 (enExample)
NZ (1) NZ730012A (enExample)
PH (1) PH12017500488A1 (enExample)
PL (3) PL3604294T3 (enExample)
PT (3) PT3929190T (enExample)
RS (3) RS66529B1 (enExample)
RU (1) RU2727700C2 (enExample)
SG (1) SG11201701960XA (enExample)
SI (3) SI3929190T1 (enExample)
SM (3) SMT202000059T1 (enExample)
TW (2) TWI664173B (enExample)
WO (1) WO2016060443A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102487451B1 (ko) * 2014-10-13 2023-01-11 주식회사유한양행 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
US10435388B2 (en) 2016-01-07 2019-10-08 Cs Pharmatech Limited Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
KR102444835B1 (ko) * 2016-05-26 2022-09-19 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
MY199042A (en) * 2017-06-13 2023-10-11 Beijing Adamadle Biotechnology Llc Aminopyrimidine compound, preparation method therefor and use thereof
FI3658552T3 (fi) * 2017-07-28 2023-11-16 Yuhan Corp Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa
CN111295381A (zh) * 2017-07-28 2020-06-16 株式会社柳韩洋行 可用于合成抗蛋白激酶的选择性抑制剂的中间体及其制备方法
PT3658553T (pt) * 2017-07-28 2022-09-23 Yuhan Corp Intermediários úteis para a síntese de derivados de aminopirimidina, processo para preparar os mesmos, e processo para preparar derivados de aminopirimidina usando os mesmos
WO2019042187A1 (zh) * 2017-08-30 2019-03-07 深圳市塔吉瑞生物医药有限公司 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN108047207A (zh) * 2018-01-30 2018-05-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
WO2020055756A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
JP7240032B2 (ja) * 2018-12-21 2023-03-15 深▲チェン▼市塔吉瑞生物医薬有限公司 プロテインキナーゼ活性を阻害するためのアミノピリミジン系化合物
EP3931224A4 (en) 2019-02-26 2023-03-01 Janssen Biotech, Inc. COMBINATION TREATMENTS AND PATIENT STRATIFICATION WITH ANTI-EGFR/C-MET BISPECIFIC ANTIBODIES
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
CN113993866B (zh) * 2019-03-19 2022-10-28 株式会社沃若诺伊 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
AU2020250832A1 (en) 2019-03-29 2021-11-11 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
CN111747931A (zh) 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
CA3140360A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
CN110128354A (zh) * 2019-06-20 2019-08-16 大连大学 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
KR20220130190A (ko) 2020-01-20 2022-09-26 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (ko) * 2020-06-08 2021-12-15 주식회사 종근당 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
US20230321087A1 (en) 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
TWI867047B (zh) * 2020-09-18 2024-12-21 南韓商沃若諾伊公司 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
KR20220085735A (ko) * 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
KR20220152508A (ko) * 2021-05-07 2022-11-16 보로노이바이오 주식회사 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
CA3180295A1 (en) * 2021-05-17 2022-11-24 Youn Ho Lee Heteroaryl derivative compounds, and uses thereof
EP4349835A4 (en) 2021-06-01 2025-06-25 Hangzhou Solipharma Co., Ltd. Hydrated crystal form of lazertinib methanesulfonate, process for its preparation and use thereof
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
AU2023246862A1 (en) 2022-03-31 2024-10-31 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
IL317733A (en) 2022-06-27 2025-02-01 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2024096624A1 (en) * 2022-11-03 2024-05-10 Voronoi Inc. Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor
CN116655600B (zh) * 2023-05-23 2025-08-22 江南大学 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532635A (ja) 2000-02-17 2003-11-05 アムジエン・インコーポレーテツド キナーゼ阻害薬
US20100029610A1 (en) 2008-06-27 2010-02-04 Avila Therapeutics, Inc. Heteroaryl Compounds and Uses Thereof
WO2011060295A1 (en) 2009-11-13 2011-05-19 Genosco Kinase inhibitors
JP2013544273A (ja) 2011-07-27 2013-12-12 アストラゼネカ アクチボラグ ２−（２，４，５−置換−アニリノ）ピリミジン化合物
WO2015025197A1 (en) 2013-08-22 2015-02-26 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
CN104788427A (zh) 2015-02-05 2015-07-22 上海泓博智源医药技术有限公司 3-(2-嘧啶氨基)苯基丙烯酰胺类化合物及其应用
WO2015188777A1 (en) 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
KR101671348B1 (ko) 2011-02-25 2016-11-01 주식회사유한양행 다이아미노피리미딘 유도체 및 그의 제조방법
KR102073854B1 (ko) * 2014-10-13 2020-02-05 주식회사유한양행 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172005B1 (en) 1997-03-11 2001-01-09 E. I. Du Pont De Nemours And Company Heteroaryl azole herbicides
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
KR100947185B1 (ko) 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US7514445B2 (en) 2001-11-01 2009-04-07 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors)
MXPA05005547A (es) 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP4428565B2 (ja) 2004-10-05 2010-03-10 東京エレクトロン株式会社 処理液塗布装置
MX2007004488A (es) 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
WO2006074057A2 (en) 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (ja) 2005-07-13 2012-08-22 Ｎｔｎ株式会社 グリース組成物および該グリース封入転がり軸受
AU2006283935A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag Fused pyrazole as p38 MAP kinase inhibitors
JP2007117465A (ja) 2005-10-28 2007-05-17 Sharp Corp 集塵器およびそれを備えた電気掃除機
JP2009531943A (ja) 2006-03-29 2009-09-03 ケーティーフリーテル・カンパニー・リミテッド デジタル処理装置及びこれを用いた付加サービス提供方法
WO2007117465A2 (en) 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
CN101460491A (zh) 2006-04-12 2009-06-17 惠氏公司 苯胺基嘧啶苯基和苯并噻吩类似物
US7687522B2 (en) 2006-12-20 2010-03-30 Amgen Inc. Substituted pyridines and pyrimidines and their use in treatment of cancer
CA2760794C (en) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
NZ627113A (en) 2012-01-20 2016-07-29 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
WO2014040555A1 (zh) * 2012-09-12 2014-03-20 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
DK3157916T3 (en) 2014-06-19 2019-03-18 Ariad Pharma Inc HETEROARYL COMPOUNDS FOR CHINESE INHIBITION

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532635A (ja) 2000-02-17 2003-11-05 アムジエン・インコーポレーテツド キナーゼ阻害薬
US20100029610A1 (en) 2008-06-27 2010-02-04 Avila Therapeutics, Inc. Heteroaryl Compounds and Uses Thereof
WO2011060295A1 (en) 2009-11-13 2011-05-19 Genosco Kinase inhibitors
KR101671348B1 (ko) 2011-02-25 2016-11-01 주식회사유한양행 다이아미노피리미딘 유도체 및 그의 제조방법
JP2013544273A (ja) 2011-07-27 2013-12-12 アストラゼネカ アクチボラグ ２−（２，４，５−置換−アニリノ）ピリミジン化合物
WO2015025197A1 (en) 2013-08-22 2015-02-26 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
WO2015188777A1 (en) 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
KR102073854B1 (ko) * 2014-10-13 2020-02-05 주식회사유한양행 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
CN104788427A (zh) 2015-02-05 2015-07-22 上海泓博智源医药技术有限公司 3-(2-嘧啶氨基)苯基丙烯酰胺类化合物及其应用

Also Published As

Publication number Publication date
CN111686110A (zh) 2020-09-22
JP6754864B2 (ja) 2020-09-16
PT3207035T (pt) 2020-02-19
PT3604294T (pt) 2021-07-29
SI3604294T1 (sl) 2021-08-31
EP3604294A1 (en) 2020-02-05
CN106795144A (zh) 2017-05-31
EP3929190A1 (en) 2021-12-29
HUS2500023I1 (hu) 2025-06-28
DK3207035T3 (da) 2020-01-27
PL3929190T3 (pl) 2025-06-09
MX2020002168A (es) 2021-09-07
RU2017116598A (ru) 2018-11-21
KR102662358B1 (ko) 2024-04-30
HRP20210949T1 (hr) 2021-09-03
EP3207035A4 (en) 2018-03-14
HUE070874T2 (hu) 2025-07-28
CN106795144B (zh) 2020-06-16
RU2017116598A3 (enExample) 2018-11-21
LT3604294T (lt) 2021-07-26
KR20200014944A (ko) 2020-02-11
SMT202100266T1 (it) 2021-07-12
LTPA2025522I1 (enExample) 2025-06-25
HUE048006T2 (hu) 2020-05-28
JP2020196740A (ja) 2020-12-10
JP6524221B2 (ja) 2019-06-05
JP2017530999A (ja) 2017-10-19
MX385942B (es) 2025-03-18
WO2016060443A3 (en) 2016-06-23
KR20230010836A (ko) 2023-01-19
CY1122737T1 (el) 2021-03-12
NO2025025I1 (no) 2025-06-05
TWI730331B (zh) 2021-06-11
USRE50528E1 (en) 2025-08-12
EP3929190B1 (en) 2024-12-25
BR112017007769A2 (pt) 2018-01-16
MX2017003181A (es) 2017-07-20
FR25C1021I1 (fr) 2025-08-01
NL301329I2 (nl) 2025-09-09
RS66529B1 (sr) 2025-03-31
SG11201701960XA (en) 2017-04-27
TWI664173B (zh) 2019-07-01
PH12017500488A1 (en) 2017-07-31
LT3929190T (lt) 2025-02-25
HUE054848T2 (hu) 2021-09-28
SI3929190T1 (sl) 2025-04-30
MX2021010761A (es) 2022-06-09
KR20210011068A (ko) 2021-01-29
ES2770058T3 (es) 2020-06-30
SMT202000059T1 (it) 2020-03-13
RU2020123547A (ru) 2020-08-18
KR102208775B1 (ko) 2021-01-28
AU2015331166B2 (en) 2018-04-26
DK3604294T3 (da) 2021-06-28
EP4421069A1 (en) 2024-08-28
US9593098B2 (en) 2017-03-14
EP3207035B1 (en) 2019-11-20
FI3929190T3 (fi) 2025-02-28
JP2019163277A (ja) 2019-09-26
KR20240074820A (ko) 2024-05-28
RS61865B1 (sr) 2021-06-30
CA2962914A1 (en) 2016-04-21
CA2962914C (en) 2018-10-23
BR112017007769B1 (pt) 2023-10-10
EP3604294B1 (en) 2021-05-05
RU2727700C2 (ru) 2020-07-23
PL3604294T3 (pl) 2021-11-02
NZ730012A (en) 2019-06-28
HRP20200201T1 (hr) 2020-05-15
TW201938553A (zh) 2019-10-01
DK3929190T3 (da) 2025-02-24
EP4421069B1 (en) 2025-12-10
CN111686110B (zh) 2023-06-16
SI3207035T1 (sl) 2020-04-30
RS59900B1 (sr) 2020-03-31
KR102073854B1 (ko) 2020-02-05
LT3207035T (lt) 2020-02-25
TW201619150A (zh) 2016-06-01
PT3929190T (pt) 2025-02-19
US20160102076A1 (en) 2016-04-14
SMT202500069T1 (it) 2025-03-12
CY1124359T1 (el) 2022-07-22
ES2879474T3 (es) 2021-11-22
PL3207035T3 (pl) 2020-06-01
EP3207035A2 (en) 2017-08-23
KR20170066650A (ko) 2017-06-14
AU2015331166A1 (en) 2017-03-30
ES3009926T3 (en) 2025-03-31
FIC20250023I1 (fi) 2025-06-06
HRP20250213T1 (hr) 2025-04-25
WO2016060443A2 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
USRE50528E1 (en) Compounds and compositions for modulating EGFR mutant kinase activities
RU2838180C1 (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
RU2822389C2 (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
HK40109469A (en) Compounds and compositions for modulating egfr mutant kinase activities
HK40037313A (en) Compounds and compositions for modulating egfr mutant kinase activities
HK40037313B (en) Compounds and compositions for modulating egfr mutant kinase activities
BR122023014950B1 (pt) Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos
HK1236928A1 (en) Compounds and compositions for modulating egfr mutant kinase activities
HK1236928B (zh) 用於调节egfr突变体激酶活性的化合物和组合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A17-div-PA0104

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4